INHIBITOR THERAPTICS INC vs. NVIDIA Corporation
INHIBITOR THERAPTICS INC and NVIDIA Corporation are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| INTI | NVDA | |
|---|---|---|
| Market Cap | — | $5.16 trillion |
| Revenue (TTM) | — | $253.49 billion |
| Net Income (TTM) | — | $159.61 billion |
INTI and NVDA split the size & scale factors evenly.
Valuation
| INTI | NVDA | |
|---|---|---|
| P/E Ratio | — | 32.11 |
| Price / Book | — | 26.40 |
| Price / Sales | — | 20.36 |
INTI and NVDA split the valuation factors evenly.
Profitability
| INTI | NVDA | |
|---|---|---|
| Net Margin | — | 62.97% |
| Return on Equity | — | 81.65% |
INTI and NVDA split the profitability factors evenly.
Dividend
| INTI | NVDA | |
|---|---|---|
| Dividend Yield | — | 0.48% |
| Payout Ratio | — | 15.31 |
INTI and NVDA split the dividend factors evenly.
Risk & Sentiment
| INTI | NVDA | |
|---|---|---|
| Short Interest | — | 0.07% |
INTI and NVDA split the risk & sentiment factors evenly.
Dig deeper: INTI overview, INTI financials, NVDA overview, NVDA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.